Carcinosarcoma: Clinical Trials

3 trials for Carcinosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 3

Follow Carcinosarcoma: new trials by email Literature Review of Carcinosarcoma trials Research Report on Carcinosarcoma

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Camrelizumab Combined With Apatinib - PD-1 Immunotherapy, VEGFR-TKI
Phase 2UnknownFudan University452021-11-212022-03-04
Nivolumab for Recurrent/Metastatic Carcinosarcoma
nivolumab - Recurrent/Metastatic Carcinosarcoma
Phase 2UnknownYonsei University282019-11-132022-02-04
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
Paclitaxel, Cediranib, Olaparib - Carcinosarcoma, Endometrial Neoplasms
Phase 2UnknownUniversity of Manchester1242018-05-172022-03-02

Narrower conditions

Carcinoma (1)  ·  Endometrial Neoplasms (1)  ·  Neoplasms (1)

Broader conditions

Neoplasms by Histologic Type (3)  ·  Neoplasms, Complex and Mixed (3)  ·  Neoplasms, Connective and Soft Tissue (3)  ·  Sarcoma (3)  ·  Neoplasms (2)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Urogenital Diseases (1)  ·  Urogenital Neoplasms (1)  ·  Uterine Diseases (1)

Interventions

Nivolumab (1)  ·  Paclitaxel (1)  ·  apatinib (1)  ·  cediranib (1)  ·  olaparib (1)

Sponsors

Fudan University (1)  ·  University of Manchester (1)  ·  Yonsei University (1)

Countries

China (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Gordon Jayson (1)

Results publications

PMID 42339309

NIH funding

2016 (1)